Evidence map›Paper›PMID 41882179›Full record

ArticleNature cancer2026

Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma.

Felix Czernilofsky, Anna Mathioudaki, Lea Jopp-Saile, Raphael Lutz, Dominik Vonficht, Xi Wang, Christina Schniederjohann, Harald Voehringer, Tobias Roider, Marc-Andrea Baertsch and 29 more

Abstract read
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Felix Czernilofsky *Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Anna Mathioudaki *European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4617-7015
Lea Jopp-Saile *Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
Raphael LutzDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Dominik VonfichtFaculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
Xi WangDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Christina SchniederjohannDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Harald VoehringerEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Tobias RoiderDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Marc-Andrea BaertschDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4000-6904
Claus RodemerDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Henry Löffler-WirthInterdisciplinary Centre for Bioinformatics (IZBI), University of Leipzig, Leipzig, Germany.
Michael GrauDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Donnacha FitzgeraldDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4927-7484
Johannes MammenDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Jan KoslaDivision of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
Nora LiebersDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.ORCID http://orcid.org/0009-0008-3887-9416
Peter-Martin BruchDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-9992-3109
Diana Ordoñez-RuedaEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Alexander BrobeilDepartment of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Gunhild MechtersheimerDepartment of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Caroline PabstDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-9716-5909
Carsten Müller-TidowDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7166-5232
Andreas TrumppHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6212-3466
Marc SeifertDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.ORCID http://orcid.org/0000-0001-9453-369X
Frank NeumannKite, a Gilead Company, Santa Monica, CA, USA.
Mathias HeikenwälderDivision of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-3135-2274
Vladimir BenesEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-0352-2547
Wolfgang HuberEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Jörg DistlerDepartment of Rheumatology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.ORCID http://orcid.org/0000-0001-7408-9333
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.ORCID http://orcid.org/0000-0002-4728-1693
Hans BinderInterdisciplinary Centre for Bioinformatics (IZBI), University of Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0002-2242-4678
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Garry P NolanDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8862-9043
Moritz GerstungDivision of AI in Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6709-963X
Judith B ZauggEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany. judith.zaugg@unibas.ch.ORCID http://orcid.org/0000-0001-8324-4040
Daniel HübschmannHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany. d.huebschmann@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-6041-7049
Simon HaasBerlin Institute of Health (BIH), Charité Universitätsmedizin Berlin, Berlin, Germany. simon.haas@bih-charite.de.ORCID http://orcid.org/0000-0001-9227-2051
Sascha DietrichDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. sascha.dietrich@embl.de.ORCID http://orcid.org/0000-0002-0648-1832

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01ZX1911ADeutsche Forschungsgemeinschaft (German Research Foundation) CRC1444Deutsche Forschungsgemeinschaft (German Research Foundation) CRC1709Deutsche Forschungsgemeinschaft (German Research Foundation) HA8790/3-1Deutsche Forschungsgemeinschaft (German Research Foundation) TRR1709
6 · The paper itself

Abstract

Lymph node (LN) function requires the organization of cells into higher-order spatial units. However, the principles governing LN architecture in health and disease remain poorly understood. Here, we used single-cell and spatial mapping to investigate the mechanisms directing immune cell organization in human LNs and its disruption in architecturally distinct lymphoma entities: indolent follicular lymphoma (FL) and aggressive diffuse large B cell lymphoma (DLBCL). Our data substantiate the central role of LN-resident stromal cells in chemokine-driven lymphocyte zonation and reveal an inflammatory feedback loop fueled by tumor-reactive T cells that triggers stromal remodeling, progressive loss of homeostatic chemokine gradients, and tissue disorganization from a non-malignant state to FL and DLBCL. Loss of homeostatic chemokines was associated with adverse patient survival, identifying the underlying architectural rearrangement as a key event during lymphomagenesis. Collectively, our results highlight the principles of LN organization and suggest how lymphoma-induced microenvironmental reprogramming drives the loss of tissue organization.

Indexed as

ChemokinesLymph NodesLymphoma, FollicularLymphoma, Large B-Cell, DiffuseStromal CellsAnimalsHumansTumor MicroenvironmentChemokines

Identifiers

PMID41882179
PMCPMC13035477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.